Search

Your search keyword '"Döring G"' showing total 41 results
Start Over Author "Döring G" Publisher elsevier b.v.
41 results on '"Döring G"'

8. A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis.

Author

Konstan, M.W., Döring, G., Heltshe, S.L., Lands, L.C., Hilliard, K.A., Koker, P., Bhattacharya, S., Staab, A., and Hamilton, A.

Subjects
*CLINICAL trials, *PLACEBOS, *CYSTIC fibrosis, *JUVENILE diseases, *LUNG disease treatment, *INFLAMMATION, *PATIENTS
Abstract

Abstract: Background: Airway inflammation, mediated in part by LTB4, contributes to lung destruction in patients with cystic fibrosis (CF). LTB4-receptor inhibition may reduce airway inflammation. We report the results of a randomized, double-blind, placebo-controlled study of the efficacy and safety of the leukotriene B4 (LTB4)-receptor antagonist BIIL 284 BS in CF patients. Methods: CF patients aged ≥6years with mild to moderate lung disease were randomized to oral BIIL 284 BS or placebo once daily for 24weeks. Co-primary endpoints were change in FEV1 and incidence of pulmonary exacerbation. Results: After 420 (155 children, 265 adults) of the planned 600 patients were randomized, the trial was terminated after a planned interim analysis revealed a significant increase in pulmonary related serious adverse events (SAEs) in adults receiving BIIL 284 BS. Final analysis revealed SAEs in 36.1% of adults receiving BIIL 284 BS vs. 21.2% receiving placebo (p=0.007), and in 29.6% of children receiving BIIL 284 BS vs. 22.9% receiving placebo (p=0.348). In adults, the incidence of protocol-defined pulmonary exacerbation was greater in those receiving BIIL 284 BS than in those receiving placebo (33.1% vs. 18.2% respectively; p=0.005). In children, the incidence of protocol-defined pulmonary exacerbation was 19.8% in the BIIL 284 BS arm, and 25.7% in the placebo arm (p=0.38). Conclusions: While the cause of increased SAEs and exacerbations due to BIIL 284 BS is unknown, the outcome of this trial provides a cautionary tale for the administration of potent anti-inflammatory compounds to individuals with chronic infections, as the potential to significantly suppress the inflammatory response may increase the risk of infection-related adverse events. [Copyright &y& Elsevier]

Published
2014
Full Text
View/download PDF

41. Antibiotic-resistant obligate anaerobes during exacerbations of cystic fibrosis patients.

Author

Worlitzsch, D., Rintelen, C., Böhm, K., Wollschläger, B., Merkel, N., Borneff-Lipp, M., and Döring, G.

Subjects
*PSEUDOMONAS aeruginosa, *STAPHYLOCOCCUS aureus, *CYSTIC fibrosis, *LUNG infections, *ANTIBIOTICS, *SPUTUM examination, *JUVENILE diseases, *METRONIDAZOLE, *STANDARD deviations, *PATIENTS
Abstract

Pseudomonas aeruginosa and Staphylococcus aureus are thought to cause the majority of lung infections in patients with cystic fibrosis (CF). However, other bacterial pathogens may contribute to the pathophysiology of lung disease. Here, obligate anaerobes were identified in a cross-sectional study, and cell numbers and antibiotic susceptibilities of facultative and obligate anaerobes from 114 sputum samples from nine children and 36 adults with CF were determined. Furthermore, in 12 CF patients, we investigated whether conventional intravenous antibiotic therapy, administered during acute exacerbations, would affect the numbers of obligate anaerobes. Fifteen genera of obligate anaerobes were identified in 91% of the CF patients. Cell numbers (mean: 2.2 × 107 ± standard deviation 6.9 × 107 CFU/mL of sputum sample) were comparable to those of P. aeruginosa and S. aureus. Staphylococcus saccharolyticus and Peptostreptococcus prevotii were most prevalent. Infection with P. aeruginosa did not increase the likelihood that obligate anaerobes are present in sputum specimens. Single obligate anaerobic species persisted for up to 11 months in sputum plugs in vivo. Patients with and without obligate anaerobes in sputum specimens did not differ in lung function. Intravenous therapy directed against P. aeruginosa during acute exacerbations increased lung function, but did not reduce the numbers of obligate anaerobes. Obligate anaerobic species differed widely in their patterns of resistance against meropenem, piperacillin–tazobactam, clindamycin, metronidazole and ceftazidime. In 58% of patients with acute exacerbations, obligate anaerobes were detected that were resistant to the antibiotics used for treatment. Antibiotic therapy, optimized to target anaerobes in addition to P. aeruginosa, may improve the management of CF lung disease. [ABSTRACT FROM AUTHOR]

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results